Background Compliance is sometimes difficult for patients treated with temozolomide, because of the inconvenience due to the high daily number of capsules needed. Studies with other drugs showed that pillboxes increased patient satisfaction. Purpose To determine if pharmaceutical information and the use of pillboxes may improve satisfaction of patients treated with temozolomide. Materials and Methods This prospective and interventional study included adult patients who picked temozolomide up in our Hospital Pharmacy (01/03/2012 to 31/08/2012). In the first visit, patients previously treated with temozolomide completed a satisfaction questionnaire, which was adapted from the ESTAR questionnaire (ARPAS study). It consisted of 9 questions to be answered from 0 (very unsatisfied) to 6 (very satisfied), and another two items about temozolomide information. In addition, pharmaceutical information and pillboxes were provided to all patients. At their next visit, patients received another questionnaire, with 6 of the previous satisfaction questions and 5 new questions about usefulness of the pillbox and of the received information. Results 35 patients were evaluated with the first questionnaire (50.69 ± 13.38 years old; 77.14% were treated with ≥3 capsules per dose) and 28 of them filled in the second questionnaire (50.32 ± 12.45 years old; 75% taking ≥3 capsules per dose). 88.57% vs. 85.71% of patients took their pills in cycles of 5 days followed by 23 days without treatment. Satisfaction pre- and post-intervention was related to: the number of capsules prescribed per dose (4.43 ± 1.60 vs. 4.96 ± 0.84), the possibility of taking their treatment everywhere (5.17 ± 0.92 vs. 5.32 ± 0.82), and the convenience of the chemotherapeutic regime (5.06 ± 0.94 vs. 5.07 ± 1.05). The usefulness of the pharmaceutical attention, the pillbox and the leaflet were valuated as 5.46 ± 0.58, 5.39 ± 0.69 and 5.68 ± 0.48, respectively. Global satisfaction with pharmaceutical attention was 5.79 ± 0.42. Conclusions In this study, information provided by hospital pharmacist and the use of pillboxes improved satisfaction in patients treated with temozolomide. No conflict of interest.

treatment due to poor tolerance. Regarding the satisfaction survey, 92.4% of the patients reported call was useful to them 95.8% were satisfied or very satisfied with care received at the FVP and at the phone call. Conclusion and Relevance Phone call after starting treatment reinforces the information given in OPU during the FVP and allows early intervention in detection and resolution of MRP. A high percentage of patients consider the project useful, showing a high degree of satisfaction with the care received.

No abstract

No abstract

BackgroundRiociguat is a relatively new drug that has been on the market for a short time. Most of the information available on the drug comes from clinical trials that led to its commercialisation.PurposeResults based on clinical practice often differ from results obtained in clinical trials. The purpose of this study was to evaluate the safety profile of riociguat in clinical practice as well as to analyse possible interactions riociguat may have when administered with other medicines used by HAP patients.Material and methodsA retrospective observational study was conducted in all patients treated with riociguat from September 2015 to 2016. Interactions were identified and classified according to their clinical relevance. The reason for suspension–interruption of treatment and clinical variability associated with adverse effects were also analysedResults43 patients were included, mean age 66±16.09 years, 65.12% women. 140 potential interactions with riociguat were recorded, belonging to 26 different drugs. 97.67% of patients had at least one interaction and the median number of interactions per patient was 3 (range 0–7). The most frequently involved drugs in these interactions were: furosemide (24.29%), omeprazole (20%) and spironolactone (18.57%). Depending on their relevance, potential interaction distribution was: 24 moderate (92.31%) and 2 severe (7.69%). In the registered interactions, the primary mechanism involved was based on the risk of hypotension (61.54%). The two most serious potential interactions were with phenytoin, which can decrease levels of riociguat, and calcium+cholecalciferol carbonate, which can modify the solubility of riociguatRegarding the safety profile, 39.53% of patients suffered any adverse reaction associated with riociguat: nervous system (30.95%), digestive (26.19%) and vascular (19.05%). 2 patients had dose reduction, 1 due to congestive heart failure, associated with the drug. A case of syncope forced suspension of the treatment.ConclusionMost of the patients included in the study had at least one potential interaction between their own medication and riociguat. Only 3 patients had dose reduction or suspension due to adverse effects related to riociguat. According to the results, it can be assumed that riociguat may be a safe drug despite the high number of potential interactions found in patients with polypharmacy.References and/or acknowledgementsCLINICAL TRIALS:PATENT-1,CHEST-1,PATENT-2 and CHEST-2.No conflict of interest